Skip to main content
AARD logo

AARD · Aardvark Therapeutics, Inc. · Holdings

Track AARD — free
$3.90 +0.16 (+4.28%)
Market Cap
$84.91M
Shares
21.88M
Volume · Oct 20 66.71K Avg daily vol (3M) 129.68K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Institutional holdings are being reconciled with SEC filings. Holder totals and changes may be incomplete until reconciliation finishes.
The Sep 30, 2026 filing window is still open — showing the latest known positions. Funds that have not filed yet carry their prior-quarter positions; a fund that filed without this stock counts as sold out. Each fund's Change is measured against its own previous reported quarter, shown in the Reported column. Pick a completed quarter in the Quarter selector below to put every fund on one quarter and see the stock-wide activity breakdown.
Holders: 69
Total Value: $54,806,223
Total Shares: 9,515,886

Institutional Ownership Trend

7 quarters

Holder Concentration

Across 71 13F filers
Top Holder
41.1%
Mar 2025 → Jun 2026 · range 36.4% – 45.1%
of institutional value
Top 5
77.0%
Mar 2025 → Jun 2026 · range 71.9% – 84.0%
of institutional value
Top 10
89.2%
Mar 2025 → Jun 2026 · range 86.5% – 95.7%
of institutional value
HHI
2,109
Mar 2025 → Jun 2026 · range 1,724 – 2,485
Moderately concentrated

Who Holds AARD

Last 7 quarters through Sep 30, 2026 (filing window open)

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Jun 30, 2026, the newest closed quarter: 71 filers, like-for-like change -7.5%; actively managed books +3.2%; index-like books -48.0%.

Holder type Share Filers Change
Registered adviser 49.9% 38 +8.8%
Exempt adviser 0.2% 1 new
Adviser 0.0% 1 -40.4%
Bank 1.6% 8 -71.9%
Non-US 0.0% 1 -93.8%
Holding company 2.6% 4 -70.4%
Benefit plan 0.0% 0 -100.0%
Unknown 45.6% 18 -3.6%

The Sep 30, 2026 filing window is still open, so its bar carries the Jun 30, 2026 positions of filers that have not filed yet.

How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 2 holders with no observed 2026-06-30 13F.

Conviction and Crowding

71 13F filers, quarter ended Jun 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
1
1.41% of filers hold it in their top 10
Mar 31, 2026: 1
Holders above 5%
0
median weight 0.000%
Mar 31, 2026: 0
Crowding
18.4%
of shares outstanding, 54th percentile
Mar 31, 2026: 15.3%
Private-fund advisers
18.0%
of shares outstanding
Institutional ownership
43.2%
60.7% of the estimated free float
Top 10 holders
89.4%
of 13F shares, Herfindahl 0.213
Active holders
+3.2%
like-for-like share change of active filers
5% stakes on record
3
0 13D, 3 13G (0 institutional, 2 passive, 1 exempt)
How long holders have held it value-weighted 4.9 quarters
Under 1 year 24.6% 1 to 3 years 75.4% 3 years or more 0.000% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $0 (0 buying, 0 selling).

Estimated Holder Cost Basis

Quarter ended Jun 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$10.29
estimated per share
Mar 31, 2026: $11.18
Quarter-end price
$5.76
implied by 13F values
Estimated gain or loss
-44.0%
price against the estimated cost
Estimated at a loss
92.0%
of costed 13F value

Estimated cost covers 93.2% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies AARD's active holders also own, quarter ended Dec 31, 2025
# Company Shared holders
1 EQ Equillium, Inc. 3
2 IVA Inventiva S.A. 4
3 VRDN Viridian Therapeutics, Inc.\DE 4
4 PALI Palisade Bio, Inc. 3
5 NUVB Nuvation Bio Inc. 3
6 CLDX Celldex Therapeutics, Inc. 3
7 URGN UroGen Pharma Ltd. 3
8 TRVI Trevi Therapeutics, Inc. 3
9 MLYS Mineralys Therapeutics, Inc. 3
10 COGT Cogent Biosciences, Inc. 3

Shareholder Targets

13F filers that own its peers but not AARD, quarter ended Dec 31, 2025

Found through its holder-overlap peers: EQ, IVA, VRDN, PALI, NUVB, CLDX, URGN, TRVI, MLYS, COGT, RVMD. 635 filers in all.

# Filer In peers
1 JANUS HENDERSON GROUP PLC Adviser, Diversified active $1,222,015,718 9 held
2 FARALLON CAPITAL MANAGEMENT LLC Registered adviser, Diversified active $1,192,518,412 5 held
3 WELLINGTON MANAGEMENT GROUP LLP Holding company, Diversified active $1,015,794,672 8 held
4 BAKER BROS. ADVISORS LP Registered adviser, Concentrated $832,549,253 3 held
5 Paradigm Biocapital Advisors LP Registered adviser, Concentrated $697,508,868 4 held
6 Bellevue Group AG Non-US, Diversified active $633,413,442 5 held
7 PRICE T ROWE ASSOCIATES INC /MD/ Registered adviser, Diversified active $615,829,666 9 held
8 Nextech Invest, Ltd. Exempt adviser, Concentrated $605,426,579 1 held
9 DEERFIELD MANAGEMENT COMPANY, L.P. Registered adviser, Diversified active $551,795,359 2 held
10 Fairmount Funds Management LLC Registered adviser, Concentrated $441,619,339 2 held

Fund Ownership of AARD by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 5.05% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 1.45% 316,893
Index ETFs 3.60% 788,665
Active ETFs 0.00% 0
Active funds 0.19% 41,077
Unclassified 0.00% 0
All registered funds 5.24% 1,146,635
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Showing 72 of 72
Export CSV
Holder Value (USD) % of 13F Shares Open
Key facts CIK 1774857 CUSIP 002942100 13F (30d) 8 filings 8 filers Visit website Investor relations